Drugs / TCR-T cells
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07342738 | Feb 2026 → Feb 2028 expected | cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05648994 | Dec 2022 → Feb 2024 | cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT06904859 | Jan → Dec 2019 | acute myeloid leukemia | Shenzhen University General Hospital | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT06094842 | Apr 2025 → Mar 2028 | prostate small cell carcinoma | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT06043713 | Dec 2023 → Jan 2028 expected | metastatic malignant neoplasm | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03891706 | Jan 2019 → Oct 2025 overdue | cancer | Guangzhou FineImmune Biotechnology Co., LTD. | Recruiting | No outcome recorded |
| Phase 1 | NCT03778814 | Dec 2018 → Dec 2029 expected | non-small cell lung carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT04677088 | Mar 2018 → Feb 2020 | hepatocellular carcinoma | Xiaoshun He | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07614048 | — | colorectal cancer, pancreatic ductal adenocarcinoma | Providence Health & Services | Temporarily not available | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR-T cells | “Cells will be administered at a dose of between 1x109 to 1x1010 TCR-T cells.” NCT07614048 ↗ |
| Known as | FHA11KRASG12V-TCR | “This phase I trial studies the side effects and best dose of autologous CD8+ and CD4+ transgenic T cells expressing high affinity KRASG12V mutation-specific T cell receptors...” NCT06043713 ↗1“Patients then receive FHA11KRASG12V-TCR IV on day 0.” NCT06043713 ↗ |
| Known as | T-cell Receptor-engineered T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06094842 ↗ |
| Known as | tumor-specific TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03891706 ↗ |
| Action | Deplete | “Test the quality and killing activity of the TCR-T cells in vitro” NCT03778814 ↗ |
| Modality | Cell therapy | “TCR-T cell immunotherapy” NCT03778814 ↗ |
| Route | Intravenous | “via vein” NCT03778814 ↗ |
| Target | KRAS | “recognize KRAS G12V” NCT06043713 ↗ |